<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39457145</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Children (Basel, Switzerland)</Title><ISOAbbreviation>Children (Basel)</ISOAbbreviation></Journal><ArticleTitle>Clinical Effectiveness of Biological Immunomodulators in SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children: A Systematic Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/children11101180</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although there is consensus to use immunoglobulins and corticosteroids as first-line treatments for multisystem inflammatory syndrome in children (MIS-C), the effectiveness of biological immunomodulators in patients refractory to standard therapy remains unclear. We aimed to outline real-world data on biological immunomodulators.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A literature search using Ovid-Medline, EMBASE, Cochrane CDSR, and KMBASE was conducted from September 2021 to August 2022; certainty of evidence was assessed via GRADE.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 258 studies, 10 were selected for analysis, of which 2 were observational studies (with control groups receiving standard therapy of either intravenous immunoglobulins and/or glucocorticoids) and 8 were single-arm studies. In all, 145 patients were treated with biological immunomodulators (anakinra (72; 49%) or infliximab (65; 44%)). In the first observational study, patients in the anakinra group initially exhibited a lower left ventricular ejection fraction than those in the control group. In the second study, patients in the infliximab group required less additional therapy and showed lower newly developed left ventricular dysfunction rate and reduced C-reactive protein levels. The clinical outcomes associated with each biological agent in single-arm studies were not reported individually.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Biological immunomodulators are feasible therapeutic options for refractory MIS-C. Nevertheless, further research is warranted to demonstrate clinical efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jimin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7375-4274</Identifier><AffiliationInfo><Affiliation>Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul 04933, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Soo-Han</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Pusan National University School of Medicine, Busan 49241, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0001-9883-0229</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Inha University College of Medicine, Inha University Hospital, Incheon 22332, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yun</LastName><ForeName>Ki Wook</ForeName><Initials>KW</Initials><Identifier Source="ORCID">0000-0002-0798-6779</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yae-Jean</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul 06351, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Giang Pham Ha</ForeName><Initials>GPH</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Medicine and Pharmacy, Ho Chi Minh 17000, Vietnam.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Miyoung</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2424-9965</Identifier><AffiliationInfo><Affiliation>Division for Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency, Seoul 04933, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Jong Gyun</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0001-5748-0015</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NP21-004, NA22-008, NA23-010</GrantID><Agency>Korean Academy of Medical Science</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Children (Basel)</MedlineTA><NlmUniqueID>101648936</NlmUniqueID><ISSNLinking>2227-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">biological immunomodulators</Keyword><Keyword MajorTopicYN="N">pediatric multisystem inflammatory disease</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457145</ArticleId><ArticleId IdType="pmc">PMC11506526</ArticleId><ArticleId IdType="doi">10.3390/children11101180</ArticleId><ArticleId IdType="pii">children11101180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Riphagen S., Gomez X., Gonzalez-Martinez C., Wilkinson N., Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–1608. doi: 10.1016/S0140-6736(20)31094-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31094-1</ArticleId><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber C.N., Patel R.S., Trachtman R., Lepow L., Amanat F., Krammer F., Wilson K.M., Onel K., Geanon D., Tuballes K., et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C) Cell. 2020;183:982–995. doi: 10.1016/j.cell.2020.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.034</ArticleId><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouldali N., Toubiana J., Antona D., Javouhey E., Madhi F., Lorrot M., Léger P.L., Galeotti C., Claude C., Widemann A., et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone with Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021;325:855–864. doi: 10.1001/jama.2021.0694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0694</ArticleId><ArticleId IdType="pmc">PMC7851757</ArticleId><ArticleId IdType="pubmed">33523115</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson L.A., Canna S.W., Friedman K.G., Gorelik M., Lapidus S.K., Bassiri H., Behrens E.M., Kernan K.F., Schulert G.S., Seo P., et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. Arthritis Rheumatol. 2022;74:e1–e20. doi: 10.1002/art.42062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42062</ArticleId><ArticleId IdType="pmc">PMC9011620</ArticleId><ArticleId IdType="pubmed">35118829</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics  Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance Updated 8 Feb 2023.  [(accessed on 15 March 2023)].  Available online:  https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/</Citation></Reference><Reference><Citation>Government of Western Australia Child and Adolescent Health Service  Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) Following SARS-CoV-2 Infection: Diagnosis and Management.  [(accessed on 15 March 2023)]; Available online:  https://pch.health.wa.gov.au/For-health-professionals/Clinical-Practice-Guidelines/Paediatric-Inflammatory-Multisystem-Syndrome.</Citation></Reference><Reference><Citation>Boretti A., Banik B. Modulation of COVID-19 cytokine storm by tocilizumab. J. Med. Virol. 2022;94:823–828. doi: 10.1002/jmv.27380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27380</ArticleId><ArticleId IdType="pmc">PMC8662023</ArticleId><ArticleId IdType="pubmed">34617604</ArticleId></ArticleIdList></Reference><Reference><Citation>Celikel E., Tekin Z.E., Aydin F., Emeksiz S., Uyar E., Ozcan S., Perk O., Sezer M., Tekgoz N., Coskun S., et al. Role of Biological Agents in the Treatment of SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children. J. Clin. Rheumatol. 2022;28:e381–e387. doi: 10.1097/RHU.0000000000001734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000001734</ArticleId><ArticleId IdType="pubmed">33843774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole L.D., Osborne C.M., Silveira L.J., Rao S., Lockwood J.M., Kunkel M.J., MacBrayne C.E., Heizer H.R., Anderson M.S., Jone P.N., et al. IVIG Compared with IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children. Pediatrics. 2021;148:e2021052702. doi: 10.1542/peds.2021-052702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-052702</ArticleId><ArticleId IdType="pubmed">34548377</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulou C., Al Obaidi M., Moraitis E., Compeyrot-Lacassagne S., Eleftheriou D., Brogan P. Management of severe hyperinflammation in the COVID-19 era: The role of the rheumatologist. Rheumatology. 2021;60:911–917. doi: 10.1093/rheumatology/keaa652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa652</ArticleId><ArticleId IdType="pmc">PMC7717388</ArticleId><ArticleId IdType="pubmed">33197261</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Haq N., Asmar B.I., Deza Leon M.P., McGrath E.J., Arora H.S., Cashen K., Tilford B., Charaf Eddine A., Sethuraman U., Ang J.Y. SARS-CoV-2-associated multisystem inflammatory syndrome in children: Clinical manifestations and the role of infliximab treatment. Eur. J. Pediatr. 2021;180:1581–1591. doi: 10.1007/s00431-021-03935-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-03935-1</ArticleId><ArticleId IdType="pmc">PMC7810600</ArticleId><ArticleId IdType="pubmed">33452570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P.Y., Day-Lewis M., Henderson L.A., Friedman K.G., Lo J., Roberts J.E., Lo M.S., Platt C.D., Chou J., Hoyt K.J., et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J. Clin. Investig. 2020;130:5942–5950. doi: 10.1172/JCI141113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141113</ArticleId><ArticleId IdType="pmc">PMC7598077</ArticleId><ArticleId IdType="pubmed">32701511</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanello C., Mercuri C., Derchi M., Trocchio C., Consolaro A., Caorsi R., Ravelli A., Rimini A., Marasini M., Gattorno M. Cardiovascular Manifestations in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 According to Age. Children. 2022;9:583. doi: 10.3390/children9050583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children9050583</ArticleId><ArticleId IdType="pmc">PMC9139768</ArticleId><ArticleId IdType="pubmed">35626760</ArticleId></ArticleIdList></Reference><Reference><Citation>Brisca G., Consolaro A., Caorsi R., Pirlo D., Tuo G., Campanello C., Castagnola E., Moscatelli A., Gattorno M., Ravelli A. Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients with MIS-C: Proposal for a Severity Score. Front. Pediatr. 2021;9:783745. doi: 10.3389/fped.2021.783745.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2021.783745</ArticleId><ArticleId IdType="pmc">PMC8721096</ArticleId><ArticleId IdType="pubmed">34988039</ArticleId></ArticleIdList></Reference><Reference><Citation>Sozeri B., Caglayan S., Atasayan V., Ulu K., Coskuner T., Pelin Akbay O., Hasbal Akkuş C., Atay G., Sali E., Karacan M. The clinical course and short-term health outcomes of multisystem inflammatory syndrome in children in the single pediatric rheumatology center. Postgrad. Med. 2021;133:994–1000. doi: 10.1080/00325481.2021.1987732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2021.1987732</ArticleId><ArticleId IdType="pmc">PMC8544667</ArticleId><ArticleId IdType="pubmed">34605352</ArticleId></ArticleIdList></Reference><Reference><Citation>Savas Sen Z., Tanir G., Gumuser Cinni R., Uysal Yazici M., Yoldas T., Ozturk Z., Han Kizilkaya M., Ozdem S., Yalcinkaya R., Ozturk C., et al. Multisystem inflammatory syndrome in children during severe acute respiratory syndrome coronavirus-2 pandemic in Turkey: A single-centre experience. J. Paediatr. Child. Health. 2022;58:129–135. doi: 10.1111/jpc.15674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jpc.15674</ArticleId><ArticleId IdType="pmc">PMC8447466</ArticleId><ArticleId IdType="pubmed">34343373</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)  Anakinra Condition: Systemic Onset Juvenile Idiopathic Arthritis with Macrophage Activation Syndrome.  [(accessed on 10 March 2023)].  Available online:  https://cdn.who.int/media/docs/default-source/essential-medicines/2021-eml-expert-committee/applications-for-addition-of-new-medicines/a.2_anakinra.pdf?sfvrsn=1de47f03_4.</Citation></Reference><Reference><Citation>Ahn J.G., Lee J.Y., Kim J., Choi S.H., Kim D.H., Yun K.W., Kim Y.J., Choi M. The clinical efficacy of biological immunomodulators in SARS-CoV-2-associated multisystem inflammatory syndrome in children: A systematic review. Authorea. 2023 doi: 10.22541/au.168354733.33969548/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.22541/au.168354733.33969548/v1</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>